Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2′-deoxyuridine (IdUrd)

Annals of Oncology

Volumn 12, Issue 5, 2001, Pages 701-707

  Galanis, E ^a   Goldberg, R ^a   Reid, J ^a   Atherton, P ^a   Sloan, J ^a   Pitot, H ^a   Rubin, J ^a   Adjei, A A ^a   Burch, P ^a   Safgren, S L ^a   Witzig, T E ^a   Ames, M M ^a   Erlichman, C ^a  

^a MAYO CLINIC   (United States)

Author keywords

IdUrd; Phase I study; Raltitrexed

Indexed keywords

DRUG METABOLITE; IDOXURIDINE; RALTITREXED;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INFUSION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SMALL INTESTINE CANCER; STEADY STATE; THROMBOCYTOPENIA; UPPER GASTROINTESTINAL TRACT;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IDOXURIDINE; MALE; MIDDLE AGED; NEOPLASMS; NUCLEIC ACID SYNTHESIS INHIBITORS; QUINAZOLINES; THIOPHENES;

EID: 17144435188     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011182123545     Document Type: Article

References (27)

1. A phase II study of Tomudex in relapsed epithelial ovarian cancer
2. ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer
3. Phase I study of the new thymidylate synthase inhibitor Tomudex (ZD1694) in patients with advanced malignancy
4. A phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors
5. Tomudex: A novel thymidylate synthase inhibitor with clinical antitumor activity in a range of solid tumours
6. Tomudex (ZD1694): Results of a randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia
7. Tomudex (ZD1694) has superior response and toxicity profiles compared to 5-fluorouracil and leucovorin (5-FU-LV) in advanced colorectal cancer (CRC): First results of a large international phase III study
8. Modulation of 5-Iodo-2-deoxyuridine metabolism and cytotoxicity in human bladder cancer cells by fluoropyrimidines
9. X-ray sensitization by halopyrimidines
10. ICI D1694 and idoxuridine: A synergistic antitumor combination
11. Clinical pharmacology of 5-iodo-2′-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation
12. Incorporation of iododeoxyuridine into DNA of granulocytes in patients
13. A monoclonal antibody reactive with 5-bromo-2-deoxyuridine that does not require DNA denaturation
14. An integrated system for monitoring, reporting and analyzing phase I oncology clinical trials
15. Nonparametric estimation of the survival distribution in censored data. Communications in Statistics
16. Significance testing of correlation using scores, ranks and modified ranks
17. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
18. Preliminary results of a multicentre randomized trial comparing 3 chemotherapy regimens (de Gramont, Lokich and raltitrexed) in metastatic colorectal cancer
19. Raltitrexed (Tomudex) plus 5-fluorouracil (5-FU): Improved palliation as second line therapy in patients with metastatic colorectal cancer
20. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro
21. Raltitrexed (Tomudex) in combination with platinum-based agents and/or anthracyclines: Preliminary results of phase I clinical trials
22. A phase I study of raltitrexed and paclitaxel given every 3 wks to patients with solid tumors
23. Tomudex (Raltitrexed) plus oxaliplatin as first-line chemotherapy in metastatic colorectal cancer (MCRC) patients: A promising combination
24. Initial clinical studies with 5-lodo-2′-deoxyruidine
25. Thymidylate synthetase catalyzed dehalogenation of 5-bromo-and 5-iodo-2′-deoxyuridylate
26. Differences in activities and substrate specificity of human and murine pyrimidine nucleoside phosphorylases: Implications for chemotherapy with 5-fluoropyrimidines
27. Interaction of Tomudex with radiation in vitro and in vivo